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Introduction {#sec1}
============

Human embryonic stem cells (hESCs) have unlimited replicative potential and are capable of differentiating into cell types from each of the three germ layers ([@bib50]). While much is known about the maintenance of pluripotency ([@bib3], [@bib4], [@bib9], [@bib19], [@bib24]), how differentiation signals regulate the dissolution of pluripotency and the establishment of phenotype is not well understood. Studies in hESCs have shown that many genes responsible for early developmental events are poised for either activation or repression by epigenetic mechanisms ([@bib1], [@bib16], [@bib47]). Once a differentiation signal has been introduced, early factors are expressed that prime the gene expression program of cells for lineage acquisition ([@bib57]). In this study, we investigated whether phenotype-associated transcription factors may play an initial role in differentiation prior to their established function in specifying lineage identity. A candidate screen of phenotypic transcription factors identified RUNX1 as selectively and transiently upregulated as early as 8 hr during mesendodermal differentiation of hESCs.

Members of the RUNX family of transcription factors have known roles in development ([@bib11]): RUNX1 is necessary for definitive hematopoiesis ([@bib37]), RUNX2 for bone formation ([@bib41]), and RUNX3 for gastrointestinal and nervous system development ([@bib20], [@bib29], [@bib30]). When genetically deleted in mice, *Runx1* causes embryonic lethality due to major defects in the formation of the fetal liver and hemorrhaging in the CNS ([@bib37], [@bib53]). Emerging evidence suggests that RUNX1 has roles in non-hematopoietic lineages ([@bib40], [@bib44], [@bib46]). Our discovery of transient upregulation of RUNX1 points to a role for RUNX1 during early mesendodermal differentiation of hESCs.

We investigated what role the early expressed phenotypic transcription factor RUNX1 might play during differentiation in addition to its known role in association with hematopoietic lineage identity. Genome-wide transcriptome analysis of RUNX1-depleted hESCs revealed that RUNX1 positively regulates transforming growth factor β2 (TGFB2) signaling and the motility of the differentiating hESCs. Importantly, genes associated with the epithelial to mesenchymal transition (EMT) were affected, with epithelial gene expression increasing in the absence of RUNX1. Exogenous reintroduction of TGFB2, but not TGFB1, ameliorates the effect of RUNX1 depletion on cell motility and the EMT process. Taken together, our results show that the selective and transient expression of RUNX1 during early hESC differentiation to mesendoderm promotes EMT and motility through regulation of the TGFB2 signaling pathway.

Results {#sec2}
=======

RUNX1 Is Transiently and Selectively Upregulated during Early Mesendodermal Differentiation of Human Embryonic Stem Cells {#sec2.1}
-------------------------------------------------------------------------------------------------------------------------

To investigate whether phenotype-associated transcription factors play a role in early hESC differentiation prior to their established role in control of lineage identity, we screened expression of candidate transcription factors using qRT-PCR analysis. We induced mesendodermal differentiation ([Figure 1](#fig1){ref-type="fig"}A) as described in [Experimental Procedures](#sec4){ref-type="sec"}, and ensured mesendodermal commitment of hESCs by evaluating the expression of known mesendoderm markers ([@bib33], [@bib48], [@bib52]). As expected *T*, *MIXL1*, and *MESP1* were upregulated ([Figure 1](#fig1){ref-type="fig"}B). We discovered *RUNX1* was the only candidate factor selectively and transiently upregulated as early as 4--8 hr following induction of differentiation ([Figure 1](#fig1){ref-type="fig"}C).

Different *RUNX1* isoforms ([Figure 1](#fig1){ref-type="fig"}D) are linked to distinct biological processes ([@bib5], [@bib8], [@bib42]). Importantly, the *RUNX1c* isoform, transcribed from the P1 promoter, is expressed at the time of emergence of definitive hematopoietic precursors, while *RUNX1b*, transcribed from the P2 promoter, is more widely expressed ([@bib45]). Therefore, we used specific primers to examine relative levels of each *RUNX1* isoform. We discovered that the *RUNX1b* isoform was the predominantly expressed transcript in two different hESC lines, the female H9 and male H1, during mesendodermal differentiation ([Figure 1](#fig1){ref-type="fig"}D).

We next examined the levels of total *RUNX1* transcripts during endodermal ([@bib12]), mesodermal ([@bib31]), and ectodermal ([@bib51]) differentiation of hESCs to determine whether expression is lineage specific ([Figure 1](#fig1){ref-type="fig"}E); lineages were confirmed using markers as previously described ([@bib52]). *RUNX1* was expressed during both endodermal and mesodermal, but not ectodermal differentiation, confirming the mesendodermal specificity. Furthermore, RNA FISH (fluorescence in situ hybridization) revealed that \>98% of colonies and \>95% of cells exhibited *RUNX1* expression during mesendodermal differentiation ([Figure 1](#fig1){ref-type="fig"}F). The majority of cells had two nuclear foci, consistent with two sites of transcription. In agreement with the RNA expression data, there was a complete lack of *RUNX1* foci in undifferentiated hESCs ([Figure 1](#fig1){ref-type="fig"}F). These findings establish that *RUNX1* transcripts are transiently and selectively expressed in mesendodermal lineage commitment.

Because several post-transcriptional mechanisms can prevent translation ([@bib22]), we investigated whether the *RUNX1* RNA was translated into protein. Both H1 and H9 hESC lines were subjected to early mesendodermal differentiation. Western blot analysis showed that RUNX1 protein was detectable by 12 hr, peaked at 48 hr, and decreased by 96 hr ([Figure 1](#fig1){ref-type="fig"}G). As expected, levels of the pluripotency marker POU5F1 decreased during differentiation ([Figure 1](#fig1){ref-type="fig"}G). Since RUNX1 protein is functionally organized in punctate nuclear foci ([@bib58], [@bib59]), we investigated its localization using immunofluorescence (IF) microscopy ([Figure 1](#fig1){ref-type="fig"}H). Undifferentiated hESCs were devoid of RUNX1 protein, but robust nuclear staining was detected in \>90% of cells by 48 hr, which corroborates the RNA expression and FISH results. Taken together, these findings demonstrate that RUNX1 upregulation is specific for early differentiation toward mesendodermal lineages.

RUNX1 Regulates Cell Motility and EMT in Differentiating hESCs {#sec2.2}
--------------------------------------------------------------

To determine the functional role of RUNX1, we performed global gene expression profiling during early mesendodermal differentiation of hESCs in which RUNX1 had been depleted ([Figure 2](#fig2){ref-type="fig"}A). Knockdown of RUNX1 was confirmed by western blot ([Figure 2](#fig2){ref-type="fig"}B), and microarray analysis was performed on total cellular RNA from uninfected, non-silencing (shNS) and RUNX1-depleted (shRUNX1) hESCs at four time points (0 hr, 8 hr, 24 hr, 72 hr) ([Figure 2](#fig2){ref-type="fig"}A). Reproducibility of gene expression datasets from three independent experiments was demonstrated by principal component analysis, which shows the undifferentiated and differentiated hESC samples in distinct clusters. As differentiation progresses, shRUNX1 samples separate away from the control samples (uninfected and shNS) ([Figure 2](#fig2){ref-type="fig"}A). Bioinformatics analyses determined that the non-silencing small hairpin RNA (shRNA) had very little effect on the time course of differentiation. Upon RUNX1 knockdown, only a small number of genes were significantly changed (1.5-fold change with a p value ≤0.05 and false discovery rate \[FDR\] p value ≤0.05) by 8 hr of differentiation (n = 31). The number of genes that were changed continued to increase by 24 hr (n = 334) and 72 hr (n = 435) ([Figure 2](#fig2){ref-type="fig"}C and [Table S2](#mmc2){ref-type="supplementary-material"}). These observations indicate that the depletion of RUNX1 affects gene expression and suggest a functional role for RUNX1 in early hESC differentiation.

We investigated which biological processes were altered by RUNX1 knockdown during mesendodermal differentiation. Functional grouping of gene ontology (GO) annotations showed that three biological processes were potentially affected: regulation of endothelial cell proliferation, smooth muscle cell migration, and cell adhesion ([Figure 2](#fig2){ref-type="fig"}D). We experimentally addressed contributions of RUNX1 in the regulation of these processes. Proliferation was assessed by measuring growth curves of pluripotent or differentiating uninfected, shNS, or shRUNX1 hESCs ([Figure 2](#fig2){ref-type="fig"}E). RUNX1 depletion had no net effect on proliferation when compared with the two controls. This observation was further confirmed by measuring active DNA synthesis using 5-bromo-2-deoxyuridine (BrdU) incorporation ([Figure 2](#fig2){ref-type="fig"}F), which showed no effect of RUNX1 knockdown on the percentage of BrdU- positive cells in pluripotent or differentiating hESCs.

The effect of RUNX1 on the migration of differentiating hESCs was examined by scratch closure assays ([Figures 2](#fig2){ref-type="fig"}G and 2H). The extent of scratch closure was measured 18 hr after scratch initiation ([Figure 2](#fig2){ref-type="fig"}G). Uninfected and shRNA control cells achieved ∼70% closure, while the shRUNX1 cells achieved only ∼40% closure ([Figure 2](#fig2){ref-type="fig"}H), indicating impaired migration upon RUNX1 depletion. Taken together with the lack of RUNX1 effect on proliferation, these findings establish a role for RUNX1 in regulating migration during early mesendodermal differentiation.

Consistent with these results, GO term analysis using DAVID revealed that genes upregulated upon knockdown of RUNX1 were involved in cell-cell adhesion and junction interactions ([Figure S1](#mmc1){ref-type="supplementary-material"}A). In addition, many of the top genes that were increased upon RUNX1 depletion during differentiation are associated with an epithelial-like phenotype ([Figure S1](#mmc1){ref-type="supplementary-material"}B). These findings led us to experimentally test whether the EMT was affected by loss of RUNX1. We evaluated the expression of several epithelial (*CDH1* \[Cadherin 1/E-Cadherin\], *OCLN* \[Occludin\], and *CLD7* \[Claudin 7\]) and mesenchymal (*VIM* \[Vimentin\], *TWIST1* \[Twist Family basic Helix-Loop-Helix Transcription Factor 1\], *ZEB2* \[Zinc Finger E-box Binding Homeobox 2\], *SNAI1* \[Snail Family Transcriptional Repressor 1\], *SNAI2* \[Snail Family Transcriptional Repressor 2\], and *CD44* \[CD44 molecule (Indian Blood Group)\]) marker genes across early mesendodermal differentiation in either shNS or shRUNX1 hESCs ([Figure 3](#fig3){ref-type="fig"}). A typical profile of cells undergoing EMT is observed in shNS hESCs, where all epithelial markers decreased and all mesenchymal markers increased at some point during differentiation ([Figure 3](#fig3){ref-type="fig"}, light gray bars). However, in the absence of RUNX1, the epithelial markers decreased initially but were restored to at least undifferentiated levels by 72 hr ([Figure 3](#fig3){ref-type="fig"}, black bars). This is consistent with RUNX1, which is expressed by 8 hr, assisting in the suppression of epithelial markers during the early stages of EMT. In contrast, the majority of mesenchymal markers were unaffected with the exception of *ZEB2*, which was not induced ([Figure 3](#fig3){ref-type="fig"}, black bars). Collectively these findings show that RUNX1 contributes to regulation of a physiological EMT that occurs during early mesendodermal differentiation.

RUNX1 Depletion Inhibits TGFB2 Signaling {#sec2.3}
----------------------------------------

Because EMT is a complex process regulated by multiple signaling pathways ([@bib13], [@bib60]), we performed signaling pathway analysis on annotated genes that changed significantly upon RUNX1 depletion ([Figure 4](#fig4){ref-type="fig"}A and [Table S3](#mmc3){ref-type="supplementary-material"}). Distinct pathways were suggested to be activated by RUNX1 knockdown at each time point, although no single pathway was suggested to be activated at all time points. Conversely, the TGFB pathway was indicated to be the most inhibited across the time course of differentiation ([Figure 4](#fig4){ref-type="fig"}A and [Table S3](#mmc3){ref-type="supplementary-material"}), which suggests that RUNX1 activates TGFB signaling during mesendodermal differentiation.

To investigate directly how RUNX1 regulates the TGFB signaling pathway, we examined expression of the *TGFB* ligands upon RUNX1 depletion ([Figure 4](#fig4){ref-type="fig"}B). *TGFB1* and *TGFB2* RNA exhibited sequential and significant upregulation (\>15 fold) during hESC differentiation, while *TGFB3*, which is expressed at relatively low levels, remained unchanged. Importantly, only *TGFB2* expression was significantly affected by RUNX1 depletion ([Figure 4](#fig4){ref-type="fig"}B). We also found that both *TGFB1* and *TGFB2*, but not *TGFB3*, promoters contain RUNX1 consensus sites within 1 kb of the transcription start site. We tested whether RUNX1 binds to the *TGFB* promoters using chromatin immunoprecipitation (ChIP)-qPCR. Our results show that RUNX1 selectively occupies the *TGFB2*, but not the *TGFB1*, promoter ([Figure 4](#fig4){ref-type="fig"}C), which is consistent with the effect of RUNX1 depletion on *TGFB2* expression ([Figure 4](#fig4){ref-type="fig"}B). As expected, RUNX1 occupied its own promoter, which was included as a positive control ([@bib27]). These results show that RUNX1 selectively occupies and regulates expression of the *TGFB2* gene.

We next examined whether downstream effectors of the canonical TGFB pathway were changed in the absence of RUNX1. Western blot analysis was carried out for both phospho- and total SMAD2 during mesendodermal differentiation ([Figures 4](#fig4){ref-type="fig"}D and [S2](#mmc1){ref-type="supplementary-material"}). In the control (non-silencing) time course, there was an increase in phospho-SMAD2 at 8 hr and 24 hr that decreased by 72 hr relative to total SMAD2 ([Figures 4](#fig4){ref-type="fig"}D, [S2](#mmc1){ref-type="supplementary-material"}A, and S2B). This increase coincides with the expression of *TGFB1* and *TGFB2* ligands that both signal through the SMAD pathway ([Figures 4](#fig4){ref-type="fig"}B, 4D, and [S2](#mmc1){ref-type="supplementary-material"}). Quantitation of the ratio of phospho- to total SMAD2 revealed a decrease at 24 hr and 72 hr, which is when *TGFB2* levels are decreased the most upon RUNX1 knockdown ([Figures 4](#fig4){ref-type="fig"}D, 4E, and [S2](#mmc1){ref-type="supplementary-material"}B). Together, these findings show that RUNX1 is an upstream activator of TGFB2 signaling during early mesendodermal differentiation.

TGFB2 Rescues Impaired Cell Motility and Epithelial Gene Expression Caused by RUNX1 Depletion {#sec2.4}
---------------------------------------------------------------------------------------------

The TGFB pathway is known to regulate cell migration and adhesion ([@bib56]). Our findings revealed that RUNX1 affects cell motility ([Figure 2](#fig2){ref-type="fig"}G) and specifically regulates *TGFB2* expression ([Figure 4](#fig4){ref-type="fig"}B). We directly tested whether there is a connection between the defects in motility and EMT gene expression that result from RUNX1 depletion and TGFB2 signaling. Scratch closure assays were performed to determine whether the effect of RUNX1 depletion on hESC migration could be rescued by TGFB2 ([Figure 5](#fig5){ref-type="fig"}A). We found that addition of TGFB2 significantly increased the extent of scratch closure of the shRUNX1 hESCs from ∼40% to ∼60%; TGFB1, which was included as a control, had no effect ([Figure 5](#fig5){ref-type="fig"}B). These findings are consistent with our discovery that RUNX1 occupies and transcriptionally activates the *TGFB2* gene ([Figures 4](#fig4){ref-type="fig"}B and 4C), and establish that RUNX1 regulation of hESC migration is mediated through TGFB2.

TGFB signaling can regulate EMT and the associated changes in cell adhesion and migration ([@bib36], [@bib49]). Because RUNX1 knockdown inhibits TGFB signaling ([Figure 4](#fig4){ref-type="fig"}), we evaluated whether supplementation of the shRUNX1 cultures with exogenous TGFB1 or TGFB2 could rescue the altered expression of EMT genes ([Figure 5](#fig5){ref-type="fig"}C). While TGFB2 caused significant repression of the epithelial markers to levels similar to those in shNS hESCs, TGFB1 was unable to repress most of these genes, with the exception of *CLDN7* ([Figure 5](#fig5){ref-type="fig"}C). TGFB2 failed to induce expression of *ZEB2*, the only mesenchymal marker that was not upregulated during differentiation of shRUNX1 hESCs, suggesting that the effect of TGFB2 is primarily on epithelial markers ([Figure 5](#fig5){ref-type="fig"}C). These findings indicate that knockdown of RUNX1 alleviates repression of epithelial genes ([Figure 3](#fig3){ref-type="fig"}), and addition of TGFB2 decreases the expression of these epithelial genes ([Figure 5](#fig5){ref-type="fig"}C). Taken together, our results show that the selective and transient RUNX1 expression during early mesendodermal differentiation of hESCs regulates cell motility and EMT gene expression through TGFB2.

Discussion {#sec3}
==========

In this study we discovered unexpected, transient expression of the phenotypic transcription factor RUNX1 during early mesendodermal differentiation of hESCs, which suggested that RUNX1 contributes to differentiation in addition to its established role in hematopoietic lineage identity. Our findings showed that RUNX1 regulates cell motility and gene expression during mesendodermal differentiation, specifically through TGFB2 signaling. These results reveal a previously unknown role for RUNX1 in early development.

The discovery of a burst of *RUNX1* expression was both selective and specific because none of the other examined phenotypic transcription factors showed increased expression. *RUNX1* expression from the distal P1 promoter is linked with the emergence of definitive hematopoietic stem cells ([@bib10], [@bib28], [@bib37]), but little work has been done on the role of transcripts from the more ubiquitous proximal P2 promoter ([@bib8], [@bib14], [@bib45]). In this study, the *RUNX1* transcript that we found during early mesendodermal differentiation is the *RUNX1b* isoform from the P2 promoter. Of note, in undifferentiated hESCs the *RUNX1* P2 promoter that expresses the RUNX1b transcript is bivalently marked with H3K27me3 and H3K4me3, indicating that it is poised for expression, while the P1 promoter is not ([@bib35]). Our discovery of a rapid, but substantial increase in RUNX1 expression early in differentiation to mesendoderm suggests a potential role for RUNX1 that is unrelated to hematopoiesis ([@bib70]).

We provide evidence that RUNX1 has a role in early mesendodermal differentiation of hESCs through regulation of cell migration and adhesion, as indicated by impairment of these processes upon RUNX1 depletion. These findings are consistent with the emerging role of RUNX1 in controlling cell motility and migration in other biological systems. Our laboratory has previously shown that Runx1 depletion in breast cancer cells results in a decreased migration and invasion phenotype ([@bib6]); similar results were found in ovarian cancer cells ([@bib25]). Likewise, Runx1b is responsible for inducing a cell adhesion and migration program prior to release of mouse hematopoietic stem cells from hemogenic endothelium ([@bib32]).

Gene expression profiling of early mesendodermal differentiation revealed that RUNX1 regulates TGFB signaling, which has known roles in the maintenance of pluripotency of hESCs ([@bib23], [@bib55]), differentiation ([@bib21], [@bib54]), and EMT ([@bib56]). The inhibition of motility and derepression of epithelial genes observed upon RUNX1 depletion indicates that RUNX1 is upstream of the TGFB pathway. Moreover, we found that RUNX1 specifically occupies and regulates the expression of the *TGFB2* gene, which encodes one of the three TGFB ligands. Although the TGFB ligands share greater than 70% homology ([@bib26]), studies of knockout mice show non-overlapping phenotypes, indicating that each ligand has specific functions in development ([@bib43]). Consistent with the results from these mouse models, we found that TGFB2, but not TGFB1, rescued the phenotype of RUNX1 depletion.

In conclusion, our discovery of RUNX1-mediated regulation of TGFB2 signaling provides mechanistic insights into early mesendodermal differentiation. These results also establish RUNX1 as a selective and specific regulator of cell motility and EMT-associated gene expression.

Experimental Procedures {#sec4}
=======================

Stem Cell Culture {#sec4.1}
-----------------

The female H9 (WA09) line and the male H1 (WA01) of hESCs were maintained on Matrigel and differentiated as previously reported ([@bib52]). In short, mesendoderm differentiation was induced with Knockout DMEM, containing 20% heat-inactivated defined fetal bovine serum (FBS), 1 mM L-glutamine with 1% (v/v) 2-mercaptoethanol, and 0.1 mM non-essential amino acids. Retinoic acid (RA)-induced ectodermal differentiation was induced by the addition of 1 μM all-*trans* retinoic acid (Sigma-Aldrich). The mesodermal differentiation protocol induces differentiation by introducing medium containing RPMI 1640 with B-27 supplement without insulin (Life Technologies) and 12 μM CHIR99021 (Selleck Chemicals, catalog \#S2924). For the production of endoderm, undifferentiated hESC cultures were switched to RPMI 1640 containing 1× Glutamax and 100 ng/mL activin A (R&D Systems); for treatment past 24 hr, 0.2% FBS was added.

Lentiviral RNAi {#sec4.2}
---------------

H9 hESCs plated on Matrigel were transduced in 6-well plates with lentivirus carrying shRNA designed to knock down RUNX1 (clone V2LHS_150257) or be non-silencing (\#RHS4346) using the GIPZ Lentiviral RNAi System (GE Dharmacon) in the presence of polybrene. After introduction of lentivirus, cells were spun at 2,000 rpm at 37°C for 45 min. Selection with 1 μg/mL puromycin (Sigma-Aldrich \#P7255-100MG) was performed for the first three passages after infection.

Microarray Expression Analysis {#sec4.3}
------------------------------

RNA was extracted using TRIzol and prepared for microarray analysis as described previously ([@bib52]). All target preparation and microarray hybridization/scanning was performed in the VGN Microarray Facility at the University of Vermont. The datasets generated have been deposited in the NCBI GEO database according to MIAME guidelines (GEO: [GSE74004](ncbi-geo:GSE74004){#intref0010} and [GSE79598](ncbi-geo:GSE79598){#intref0015}).

Due to evident fold-change compression, Affymetrix used a GC content leveling and signal-space transformation to reduce background levels. Analysis of data was performed using Affymetrix Expression Console Build 1.3.1.187 and the Affymetrix Transcriptome Analysis Console Version 1.0.0.234. Differential gene expression was defined as a fold change greater than 1.5, an ANOVA p value less than 0.05, and an FDR p value less than 0.05. Partek Genomic Suite software was used to generate the principal component analysis. EulerAPE version 3.0.0 was used to generate the proportional Venn diagram and then recolored ([@bib34]). Pathway analysis was performed using Ingenuity Pathways Analysis (Qiagen, [www.ingenuity.com](http://www.ingenuity.com){#intref0020}). GO term analysis was performed using DAVID (Version 6.7) ([@bib17], [@bib18]). The ClueGO plug-in for Cytoscape 2.8 (Version 1.8) was used for functional grouping GO analysis ([@bib2]).

Real-Time qPCR Analysis {#sec4.4}
-----------------------

RNA was isolated as described for microarray analysis, and cDNA was synthesized with random hexamer primers using SuperScript III First Strand Synthesis System (Life Technologies \#18080-051). qRT-PCR was performed using SYBR Green PCR Master Mix (Bio-Rad); samples were normalized to *HPRT1* and fold change was determined using the ΔΔCt method. Primers used are as specified in [Table S1](#mmc1){ref-type="supplementary-material"}.

Immunofluorescence Microscopy and RNA FISH {#sec4.5}
------------------------------------------

Cells were grown on Matrigel-coated coverslips for IF and RNA FISH. Detection of RUNX1 protein was performed using a rabbit polyclonal RUNX1 antibody (Cell Signaling \#4336). Staining was performed using a fluorescent secondary antibody to rabbit polyclonal antibodies and a goat anti-rabbit immunoglobulin G (IgG) (H + L) secondary antibody, Alexa Fluor 488 conjugate (Thermo Fisher Scientific \#A-11001). For RNA FISH, a *RUNX1* probe was created using a BAC clone (RP11-299D9) spanning the *RUNX1* gene locus, obtained from the BAC/PAC Resources at the Children\'s Hospital Oakland Research Institute from the RPCI-11 Human Male BAC Library ([@bib38], [@bib39]). The BAC clone was amplified and isolated using the Qiagen Large-Construct Kit, and labeled by nick translation using the DIG-Nick Translation Mix (Roche \#11745816910). Hybridization and detection were carried out as previously reported ([@bib7]), with the addition of a pepsin digest (5 mg/mL pepsin in a 1:2,000 dilution in 0.01 N HCl) to allow full penetrance of probe. Hybridization occurred overnight at 37°C. A rhodamine anti-digoxygenin secondary antibody (Roche \#11207750910) was used for signal detection. Images were taken on a Zeiss AxioImager microscope equipped with a Hamamatsu CCD camera and Metamorph imaging software.

Proliferation Assays {#sec4.6}
--------------------

For growth curves, cells were plated in 12-well plates. The next day, cells were counted and this value was taken as 0 hr, and differentiation was initiated in half of the plates. Counting was performed at the same time daily for up to 120 hr until confluence was reached. For the BrdU incorporation assay, cells were incubated for 30 min at 37°C with 10 μM BrdU (Roche kit \#11296 736 001) to allow for incorporation before fixation. Fixation was performed using 3.7% formaldehyde in PBS for 10 min. Cells were then permeabilized in 0.1% Triton X-100 in PBS, and washed in 0.5% BSA in PBS. For the BrdU incorporation assay, cells were treated with DNaseI (30 μg per million cells) (BD Biosciences) for 1 hr at 37°C after permeabilization to expose the incorporated BrdU. Detection was performed using a mouse monoclonal anti-BrdU antibody (clone MBG 6H8 IgG1 from Roche) and staining was performed using a mouse monoclonal F(ab′)2 goat anti-mouse IgG (H + L) secondary antibody and Alexa Fluor 647 conjugate (Life Technologies \#A-21237).

Western Blot {#sec4.7}
------------

Whole-cell lysates were generated by incubating cells in RIPA buffer for 30 min on ice, followed by sonication using a Covaris S-220 Ultrasonic Processor for 5 min. Lysates were separated in an 8% polyacrylamide gel and transferred to polyvinylidene fluoride membranes (Millipore) using an OWL semi-dry transfer apparatus. Membranes were blocked using 1% Blotting Grade Blocker Non-Fat Dry Milk (Bio-Rad) and incubated overnight at 4°C with the following primary antibodies: a rabbit polyclonal RUNX1 (Cell Signaling \#4334, 1:1,000); a goat polyclonal to POU5F1 (Santa Cruz Biotechnology \#sc-8628, 1:1,000); a rabbit polyclonal to CDK2 (M2) (Santa Cruz \#sc-163, 1:2,000); a mouse monoclonal to GAPDH (0411) (Santa Cruz \#sc-47724); a rabbit monoclonal to SMAD2 (D43B4) (Cell Signaling \#5339); and a rabbit monoclonal to pSMAD2 (Ser465/467) (138D4) (Cell Signaling \#3108). Secondary antibodies conjugated to horseradish peroxidase (Santa Cruz) were used for immunodetection, along with the Clarity Western ECL Substrate (Bio-Rad) on a Chemidoc XRS+ imaging system (Bio-Rad).

TGFB Rescues {#sec4.8}
------------

Reintroduction of TGFB1 (R&D Systems \#240-B) and TGFB2 (R&D Systems \#302-B2) reconstituted in 4 mM HCl was performed at 5.0 ng/mL.

Scratch Assays {#sec4.9}
--------------

hESCs were plated and 24 hr later were induced to differentiate, and 30 hr into differentiation mitomycin C at 10 μg/mL was introduced to inhibit cell proliferation. After 48 hr of differentiation, colonies were scratched down the center using a sterile 10-μL pipette tip. Scratches were imaged by phase-contrast microscopy directly in the center of the colony, after being washed twice with medium, and marked. The scratch was imaged 18 hr later in the marked location. The scratch area was calculated using the Scratch Assay Analyzer plug-in from MiToBo toolbox for ImageJ ([@bib15]).

Chromatin Immunoprecipitation {#sec4.10}
-----------------------------

After 2 days of mesendodermal differentiation, cells were crosslinked with 0.8% formaldehyde (Sigma-Aldrich) in PBS for 10 min. The cells were washed twice and lysed in a buffer containing 0.1% sodium deoxycholate, 0.5% N-lauroylsarcosine, 1 mM EDTA, 1 mM EGTA, 10 mM Tris-HCl (pH 8), and 1× protease inhibitor mixture. Lysates were sonicated to fragment chromatin DNA into ∼200--800 bp pieces using an S220 Sonicator (Covaris). Lysates were transferred into a buffer containing 0.1% SDS, 1 mM EDTA, 50 mM HEPES (pH 7.9), 140 mM NaCl, 1% Triton X-100, and 1× protease inhibitor mixture. Sheared chromatin was used for immunoprecipitation with RUNX1 antibody (Cell Signaling \#4334) or IgG (Millipore \#12-370) overnight at 4°C. Subsequently, the immunoprecipitation mixture was incubated with Protein-G Dynabeads (Thermo Fisher \#10003D) for an additional 3 hr at 4°C. Precipitated chromatin was washed with salt solutions of increasing concentration, and eluted into a buffer containing 1% SDS and 0.1 M NaHCO~3~. The crosslinking was reversed and DNA was recovered using the QiaQuick PCR purification kit (Qiagen \#28104).
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![RUNX1 Is Transiently Upregulated during Early Differentiation of Human Embryonic Stem Cells to Mesendodermal Lineages\
(A) Phase-contrast images of hESCs before differentiation and after 24 hr of mesendodermal differentiation. In the undifferentiated state the cells appear more epithelial-like, but after 24 hr of differentiation they appear more mesenchymal-like. Images were taken at 10× magnification.\
(B) Diagram of gene expression profile of early mesendodermal differentiation of hESCs.\
(C) Relative transcript levels of select transcription factors, including the *RUNX* family, during early mesendodermal differentiation of hESCs. Graph represents mean ± SEM from three independent experiments.\
(D) Relative levels of the *RUNX1* isoforms in both the female (H9) and male (H1) hESCs with a schematic of different *RUNX1* transcript isoforms. Graph represents mean ± SEM from three independent experiments.\
(E) Relative levels of total *RUNX1* transcript during directed differentiation to the three germ layers. No *RUNX1* transcript was detected during ectoderm differentiation. Data represent the mean ± SEM values from three independent experiments.\
(F) Representative RNA FISH images showing *RUNX1* RNA (red) at time points indicated. Nuclei are stained with DAPI (blue). Images taken at 63× magnification.\
(G) Representative western blot showing the transient increase in levels of RUNX1, and the decrease in POU5F1 in the H1 and H9 hESCs during a mesendoderm differentiation time course with CDK2 used as the loading control.\
(H) Representative immunofluorescence images showing RUNX1 (green) nuclear staining at the time points indicated. Nuclei are stained with DAPI (blue). Images taken at 63× magnification.](gr1){#fig1}

![Knockdown of RUNX1 Impairs the Migration Ability, but Not the Proliferation Rate, of hESCs during Mesendoderm Differentiation\
(A) Principal component analysis of the time points, replicates, and treatments for mesendodermal differentiation of hESCs from transcriptome profiling. Four time points (undifferentiated \[0h; red\], 8 hr \[8h; purple\], 1 day \[24h; blue\], and 3 days \[72h; green\]) (n = 3 replicates from independent experiments) were analyzed by microarray analysis under three different treatments (uninfected \[squares\], non-silencing infected \[triangles\], and shRUNX1 \[circles\]).\
(B) Representative western blot comparing the levels of RUNX1 in hESCs treated with either non-silencing shRNA or RUNX1 shRNA differentiating to mesendoderm, confirming that RUNX1 is knocked down in shRUNX1 hESCs.\
(C) Venn diagram of the number of genes with expression changes greater than 1.5-fold, and p value and FDR p values less than 0.05, at each differentiation time point under shRUNX1 treatment compared with non-silencing infected hESCs. The total number of genes changed at each time point is in brackets.\
(D) ClueGO analysis of genes with significant expression changes reveals three biological processes that might be affected by RUNX1 knockdown.\
(E) Growth curves for hESCs either uninfected (blue), non-silencing infected (red), or with shRUNX1 (green) under pluripotent and mesendoderm differentiation conditions. Line graph represents mean ± SEM from three independent experiments.\
(F) Percentage of cells staining positive for BrdU with a 30-min pulse of labeling. Quantification of BrdU^+^ cells was performed using blind scoring in duplicate of 200 cells from immunofluorescent images. Data represent mean ± SEM from three independent experiments.\
(G) Representative phase-contrast images from a scratch closure assay. Cells were plated, differentiated for 48 hr, and after 46 hr of differentiation cells were treated with mitomycin C (to inhibit proliferation) after which a scratch was made. Closure was measured 18 hr later. Dotted lines have been added to the phase-contrast images for emphasis along the edge of the scratch after that 18 h period. All phase-contrast images were taken at 10× magnification.\
(H) Percentage of scratch closure for hESCs uninfected, non-silencing infected, and infected with shRUNX1, as quantitated by ImageJ plug-in. Ten scratches were measured for each condition, two from each of five independent experiments, and data represent mean ± SD. ^∗∗∗^p \< 0.001; NS, not significant.](gr2){#fig2}

![Genes that Regulate Epithelial to Mesenchymal Transition Are Affected by RUNX1 Knockdown\
During mesendoderm differentiation of hESCs, the levels of multiple effectors of EMT (epithelial associated \[*CDH1*, *OCLN*, and *CLD7*\] and mesenchymal associated \[*VIM*, *TWIST1*, *ZEB2*, *SNAI1*, *SNAI2*, and *CD44*\]) were measured by qRT-PCR under treatment by non-silencing infection, or shRUNX1. During the control (non-silencing) differentiation epithelial marker expression decreases and mesenchymal gene expression increases. However, with shRUNX1 treatment, the epithelial marker genes fail to be suppressed and *ZEB2* is not induced. Data shown represent mean ± SEM from three independent experiments. p Values were determined by t test between non-silencing infected and shRUNX1 treatment at each corresponding time point (^∗^p \< 0.001). See also [Figure S1](#mmc1){ref-type="supplementary-material"}.](gr3){#fig3}

![Knockdown of RUNX1 Inhibits the TGFB Signaling Pathway, Specifically through *TGFB2*\
(A) Top signaling pathways inhibited by RUNX1 knockdown as determined by Ingenuity Pathway analysis.\
(B) Relative expression of the three *TGFB* ligands under non-silencing and shRUNX1 treatment by RT-qPCR. Data represent mean ± SEM from three independent experiments with a p value determined by t test (^∗^p \< 0.05).\
(C) ChIP-qPCR analysis for RUNX1 binding sites in the promoters of the *TGFB1*, *TGFB2*, and *RUNX1* promoters. Experiments were carried out at the peak of RUNX1 protein expression at 48 hr of differentiation. Data represent mean ± SEM of fold enrichment from four independent experiments with a p value determined by t test comparing specific signaling with signal obtained from the IgG control (^∗^p \< 0.05).\
(D) Representative western blot showing a decrease in levels of pSMAD2 at 24 and 72 hr, with an increase in total SMAD2 levels with shRUNX1 treatment during mesendoderm differentiation.\
(E) Quantitation of western blots from four independent experiments. Data represent the mean ± SEM of the ratio of pSMAD2 over total SMAD2, and there is a significant decrease (^∗^p \< 0.05) in the ratio of pSMAD2 to total SMAD2 at 24 and 72 hr of differentiation.\
See also [Figure S2](#mmc1){ref-type="supplementary-material"}.](gr4){#fig4}

![Defects in Cell Motility and EMT Gene Expression Caused by RUNX1 Depletion Are Rescued by Reintroduction of TGFB2, but Not TGFB1\
(A) Representative phase-contrast images from a scratch closure assay. Assays were carried out as in [Figure 2](#fig2){ref-type="fig"}G, with the addition of TGFB ligand. Dotted lines have been added to the phase-contrast images for emphasis along the edge of the scratch after the 18 h closure period. All phase-contrast images were taken at 10× magnification.\
(B) Percentage of scratch closure for hESCs with non-silencing infection and shRUNX1 infection, as well as shRUNX1 cells supplemented with exogenous TGFB1 or TGFB2, as quantitated by ImageJ. Ten scratches were measured for each condition, two from each of five independent experiments, and data represent mean ± SD. p Values were determined by t test (^∗^p \< 0.05, ^∗∗∗^p \< 0.001).\
(C) The expression of the four genes that were found to be affected by RUNX1 knockdown (*CDH1*, *OCLN*, *CLD7*, and *ZEB2*) with non-silencing, shRUNX1, shRUNX1 + TGFB2, and shRUNX1 + TGFB1 over a mesendoderm differentiation time course. Data are shown as mean ± SEM from three independent experiments. p Values were determined by t test between shRUNX1 and either shRUNX1 cells supplemented with TGFB2, or TGFB1 (^\#^p \< 0.0001).](gr5){#fig5}
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